The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE−/− mouse model

GLP-1 Receptor Agonists: Effects on Cardiovascular Risk Reduction

(2012) Daniel Lorber   Cardiovascular Therapeutics

The Distinctive Nature of Atherosclerotic Vascular Disease in Diabetes: Pathophysiological and Morphological Insights

(2012) Rishi Puri et al.   Current Diabetes Reports

An overview of the pharmacokinetics, efficacy and safety of liraglutide

(2012) Bruce Bode   DIABETES RESEARCH AND CLINICAL PRACTICE

Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe −/− mice

(2012) F. Vittone et al.   DIABETOLOGIA

Liraglutide prevents diabetes progression in prediabetic OLETF rats

(2012) Nanjing Guo et al.   ENDOCRINE JOURNAL

GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic MaleApoE−/−Mice

(2012) Naim Panjwani et al.   ENDOCRINOLOGY

Treatment evaluation of liraglutide in type 2 diabetes

(2012) Ram Kela et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model

(2011) Tracey Gaspari et al.   Diabetes & Vascular Disease Research

Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice

(2011) M. Nagashima et al.   DIABETOLOGIA

DPP-4 (CD26) Inhibitor Alogliptin Inhibits Atherosclerosis in Diabetic Apolipoprotein E–Deficient Mice

(2011) Nga N Ta et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Insulin treatment attenuates diabetes-increased atherosclerotic intimal lesions and matrix metalloproteinase 9 expression in apolipoprotein E-deficient mice

(2011) Corinne A Schuyler et al.   JOURNAL OF ENDOCRINOLOGY

Endothelial Dysfunction in the Apolipoprotein E-deficient Mouse: insights into the influence of diet, gender and aging

(2011) Silvana S Meyrelles et al.   Lipids in Health and Disease

Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product–receptor axis

(2011) Takanori Matsui et al.   PHARMACOLOGICAL RESEARCH

Stabilisation of atherosclerotic plaques

(2011) Jacob Fog Bentzon et al.   THROMBOSIS AND HAEMOSTASIS

Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4

(2010) M. Arakawa et al.   DIABETES

RETRACTED ARTICLE: A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells

(2010) Y. Hattori et al.   DIABETOLOGIA

The Fat-Fed Apolipoprotein E Knockout Mouse Brachiocephalic Artery in the Study of Atherosclerotic Plaque Rupture

(2010) Andrew R. Bond et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes

(2010) Gina J. Ryan et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Incretin-Based Therapies for Type 2 Diabetes Mellitus: Current Status and Future Prospects

(2010) Scott R Drab   PHARMACOTHERAPY

A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules

(2009) Hongbin Liu et al.   JOURNAL OF ENDOCRINOLOGY

Exendin-(9–39) Corrects Fasting Hypoglycemia inSUR-1–/–Mice by Lowering cAMP in Pancreatic β-Cells and Inhibiting Insulin Secretion

(2008) Diva D. De León et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The Role of Incretins in Glucose Homeostasis and Diabetes Treatment

(2008) W. Kim et al.   PHARMACOLOGICAL REVIEWS